Kate Kelley, MD, UCSF Health

home / authors / kate-kelley,-md,-ucsf-health

Articles

Emerging Therapies for HCC Management

Emerging Therapies for HCC Management

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Metastatic HCC Unmet Needs

Metastatic HCC Unmet Needs

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

I/O Second-Line Treatment

I/O Second-Line Treatment

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

REACH and REACH2 Trial Overview

REACH and REACH2 Trial Overview

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Second-Line Therapy: Monoclonal Antibody

Second-Line Therapy: Monoclonal Antibody

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Second-Line Sequencing After IMbrave150 Regimen

Second-Line Sequencing After IMbrave150 Regimen

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

R/R HCC: Second-Line Options

R/R HCC: Second-Line Options

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Frontline I/O: Clinical Trial Overviews

Frontline I/O: Clinical Trial Overviews

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Frontline Therapy: Promising I/O Combinations

Frontline Therapy: Promising I/O Combinations

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Phase 3 IMbrave150 Trial

Phase 3 IMbrave150 Trial

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Frontline Decision Factors for Metastatic Disease

Frontline Decision Factors for Metastatic Disease

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

HCC Treatment Algorithm: Asia and Europe

HCC Treatment Algorithm: Asia and Europe

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Transitioning From Locoregional to Systemic Therapy

Transitioning From Locoregional to Systemic Therapy

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

HCC Diagnosis and Prognosis

HCC Diagnosis and Prognosis

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

The Evolving Role of Medical Oncologists and Hepatologists

The Evolving Role of Medical Oncologists and Hepatologists

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

HCC Global Screening Programs for At-Risk Populations

HCC Global Screening Programs for At-Risk Populations

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

HCC Etiologic Risk Factors and Global Prevalence

HCC Etiologic Risk Factors and Global Prevalence

Peter R. Galle, MD, PhD, Mainz University Medical Center;Minsig Choi, MD, Stony Brook University Hospital;Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine;Kate Kelley, MD, UCSF Health
June 29th 2020

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data